Search

Displaying results 1501 - 1510 of 6949 in total
  1. Drug

    Bedaquiline

    go.drugbank.com/drugs/DB08903
    ApprovedInvestigational

    The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. … [A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisSynonyms: 1-(6-Bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol
  2. Drug

    Zinc acetate

    go.drugbank.com/drugs/DB14487
    ApprovedInvestigational

    Mixtures: OMEGA PLUS EMULSION FOR INFUSION, OMEGA SPECIAL EMULSION FOR INFUSIONCategories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use
  3. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    [A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen]. … [A218171, A218176, A229988] The application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping to produce truncated BMD-like dystrophin proteins, which restore

  4. Drug

    Nizatidine

    go.drugbank.com/drugs/DB00585
    Approved

    A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  5. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection. … Vosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection [FDA Label].

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. … They are indicated for use as rescue therapy following use of high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid

    Categories: Detoxifying Agents for Antineoplastic Treatment
  7. Target

    Nuclear receptor subfamily 0 group B member 1

    go.drugbank.com/bio_entities/BE0000074
    TargetHumans

    Nuclear receptor that lacks a DNA-binding domain and acts as a corepressor that inhibits the transcriptional activity of other nuclear receptors through heterodimeric interactions (PubMed:12482977, PubMed

    Polypeptides: Nuclear receptor subfamily 0 group B member 1Synonyms: Nuclear receptor DAX-1
  8. Target

    Nuclear receptor subfamily 1 group D member 1

    go.drugbank.com/bio_entities/BE0009347
    TargetHumans

    Acts as a receptor for heme which stimulates its interaction with the NCOR1/HDAC3 corepressor complex, enhancing transcriptional repression. … Binds as a monomer to a response element composed of the consensus half-site motif 5'-[A/G]GGTCA-3' preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a direct repeat of the core motif spaced

    Polypeptides: Nuclear receptor subfamily 1 group D member 1
  9. Target

    Leucine-rich repeat serine/threonine-protein kinase 2

    go.drugbank.com/bio_entities/BE0009457
    TargetHumans

    Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose-6-phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent

    Polypeptides: Leucine-rich repeat serine/threonine-protein kinase 2
  10. Target

    Tyrosine-protein phosphatase non-receptor type substrate 1

    go.drugbank.com/bio_entities/BE0010650
    TargetHumans

    Receptor for THBS1 (PubMed:24511121). Interaction with THBS1 stimulates phosphorylation of SIRPA (By similarity). … Involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin.

    Polypeptides: Tyrosine-protein phosphatase non-receptor type substrate 1Synonyms: Inhibitory receptor SHPS-1, Macrophage fusion receptor